Literature DB >> 23907567

Peroxiredoxins, thioredoxin, and Y-box-binding protein-1 are involved in the pathogenesis and progression of dialysis-associated renal cell carcinoma.

Fumiyoshi Fushimi1, Kenichi Taguchi, Hiroto Izumi, Kimitoshi Kohno, Michihiko Kuwano, Mayumi Ono, Yutaka Nakashima, Tetsuro Takesue, Seiji Naito, Yoshinao Oda.   

Abstract

Patients with end-stage renal disease are exposed to increased oxidative stress and impairment of antioxidant mechanisms. We focused on dialysis renal cell carcinoma (RCC), including epithelial hyperplasia in acquired cystic disease of the kidney (ACDK). We attempted to obtain insight into the carcinogenesis and tumor progression in terms of cellular defense mechanisms associated with oxidative stress by investigating the expression of antioxidant proteins by immunohistochemistry. We evaluated retrospectively 43 cases of dialysis RCC and, as a control group, 49 cases of sporadic RCC. Peroxiredoxin (Prx) 1, 3, 4, 5, and 6 expression in dialysis RCC was positively correlated with the duration of dialysis. In epithelial hyperplasia, in 17 cases of acquired cystic disease of the kidney, Prxs and thioredoxin were highly expressed. Moreover, in dialysis RCC, Prx 3, 4, and 5 immunoreactivity and nuclear expression of Y-box-binding protein-1 were higher than in sporadic RCC. In dialysis RCC, Prx 3, 4, and 5 immunoreactivity positively correlated with the Fuhrman nuclear grade. These data suggest that oxidative stress during dialysis enhances antioxidant activity, with an inhibiting effect on carcinogenesis. Once cancer has developed, antioxidant activity might have a stimulating effect on the progression of dialysis RCC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23907567     DOI: 10.1007/s00428-013-1460-y

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  30 in total

Review 1.  Acquired cystic kidney disease.

Authors:  P L Choyke
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

2.  A molecular classification of papillary renal cell carcinoma.

Authors:  Ximing J Yang; Min-Han Tan; Hyung L Kim; Jonathon A Ditlev; Mark W Betten; Carolina E Png; Eric J Kort; Kunihiko Futami; Kyle A Furge; Masayuki Takahashi; Hiro-Omi Kanayama; Puay Hoon Tan; Bin Sing Teh; Chunyan Luan; Kim Wang; Michael Pins; Maria Tretiakova; John Anema; Richard Kahnoski; Theresa Nicol; Walter Stadler; Nicholas G Vogelzang; Robert Amato; David Seligson; Robert Figlin; Arie Belldegrun; Craig G Rogers; Bin Tean Teh
Journal:  Cancer Res       Date:  2005-07-01       Impact factor: 12.701

3.  Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.

Authors:  Satish K Tickoo; Mariza N dePeralta-Venturina; Lara R Harik; Heath D Worcester; Mohamed E Salama; Andrew N Young; Holger Moch; Mahul B Amin
Journal:  Am J Surg Pathol       Date:  2006-02       Impact factor: 6.394

4.  Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma.

Authors:  M A Carducci; S Piantadosi; C R Pound; J I Epstein; J W Simons; F F Marshall; A W Partin
Journal:  Urology       Date:  1999-01       Impact factor: 2.649

5.  Sulfiredoxin-Peroxiredoxin IV axis promotes human lung cancer progression through modulation of specific phosphokinase signaling.

Authors:  Qiou Wei; Hong Jiang; Zhen Xiao; Alyson Baker; Matthew R Young; Timothy D Veenstra; Nancy H Colburn
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-12       Impact factor: 11.205

Review 6.  What we know about oxidative stress in patients with chronic kidney disease on dialysis--clinical effects, potential treatment, and prevention.

Authors:  Lucia Del Vecchio; Francesco Locatelli; Marina Carini
Journal:  Semin Dial       Date:  2011-02-07       Impact factor: 3.455

7.  Genotoxic stress-induced nuclear localization of oncoprotein YB-1 in the absence of proteolytic processing.

Authors:  S B Cohen; W Ma; V A Valova; M Algie; R Harfoot; A G Woolley; P J Robinson; A W Braithwaite
Journal:  Oncogene       Date:  2009-10-19       Impact factor: 9.867

8.  Oxidative stress and DNA hypermethylation status in renal cell carcinoma arising in patients on dialysis.

Authors:  Y Hori; Y Oda; K Kiyoshima; Y Yamada; Y Nakashima; S Naito; M Tsuneyoshi
Journal:  J Pathol       Date:  2007-06       Impact factor: 7.996

9.  Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma.

Authors:  Yoshinao Oda; Kenichi Kohashi; Hidetaka Yamamoto; Sadafumi Tamiya; Kimitoshi Kohno; Michihiko Kuwano; Yukihide Iwamoto; Tatsuro Tajiri; Tomoaki Taguchi; Masazumi Tsuneyoshi
Journal:  Cancer Sci       Date:  2008-04       Impact factor: 6.716

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  4 in total

1.  Overexpression of YB1 and EZH2 are associated with cancer metastasis and poor prognosis in renal cell carcinomas.

Authors:  Yong Wang; Yajing Chen; Hua Geng; Can Qi; Yunde Liu; Dan Yue
Journal:  Tumour Biol       Date:  2015-04-17

2.  C1QBP Regulates YBX1 to Suppress the Androgen Receptor (AR)-Enhanced RCC Cell Invasion.

Authors:  Dan Yue; Yong Wang; Yin Sun; Yuanjie Niu; Chawnshang Chang
Journal:  Neoplasia       Date:  2017-01-17       Impact factor: 5.715

3.  Overexpression of YB1 C-terminal domain inhibits proliferation, angiogenesis and tumorigenicity in a SK-BR-3 breast cancer xenograft mouse model.

Authors:  Jian-Hong Shi; Nai-Peng Cui; Shuo Wang; Ming-Zhi Zhao; Bing Wang; Ya-Nan Wang; Bao-Ping Chen
Journal:  FEBS Open Bio       Date:  2016-01-11       Impact factor: 2.693

Review 4.  Renal Cell Carcinoma in End-Stage Renal Disease: A Review and Update.

Authors:  Ziad M El-Zaatari; Luan D Truong
Journal:  Biomedicines       Date:  2022-03-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.